Home Physical Sciences Development of cream to enhance the antifungal activity and reduce the side effects of fluconazole for the treatment of Candida albicans
Article
Licensed
Unlicensed Requires Authentication

Development of cream to enhance the antifungal activity and reduce the side effects of fluconazole for the treatment of Candida albicans

  • Navya Ajitkumar Bhaskaran , Salwa , Amanda Velinna Fernandes , Gabriela Volfová , Chinna Raja Pydi , Lalit Kumar EMAIL logo , Ruchi Verma , Shirleen Miriam Marques and Rupesh Kalidas Shirodkar
Published/Copyright: April 5, 2022
Become an author with De Gruyter Brill

Abstract

The aim of the present study was to formulate a fluconazole cream for the treatment of Candida albicans. The optimized cream formulation was prepared using stearic acid, oleic acid, beeswax and borax. The uniform distribution of the active ingredient fluconazole could be confirmed in all formulated creams. The FC-C-C formulation showed satisfactory spreadability and extrudability. FC-C-C delivered (95.07 ± 15.85)% in only 36 h, and the formulation released the drug by an anomalous diffusion mechanism. The viscosity of FC-C-C was found to be (63.20 ± 0.83) cP. The antifungal study and animal studies confirmed that the prepared formulation is non-irritant and has an enhanced antifungal activity that reduces the side effects of fluconazole. The studies confirm that the prepared formulation may be useful for the treatment of Candida albicans.


Corresponding author: Lalit Kumar, Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education (MAHE), Manipal 576 104, Udupi, Karnataka, India, E-mail:

Acknowledgements

Authors are thankful to Ipca Laboratories, Mumbai, India for providing drug as a gift sample. Authors also acknowledge the support of Manipal Academy of Higher Education (MAHE), Manipal, Karnataka, India for providing infrastructural facilities.

  1. Author contributions: Authors contributed equally.

  2. Research funding: None declared.

  3. Conflict of interest statement: The authors declared that there is no conflict of interest in this work.

References

1. Shetty, S., Jose, J., Kumar, L., Charyulu, R. N. Novel ethosomal gel of clove oil for the treatment of cutaneous candidiasis. J. Cosmet. Dermatol. 2019, 18, 862–869; https://doi.org/10.1111/jocd.12765.Search in Google Scholar

2. Reddy, R. S., Kumar, L., Pydi, C. R., Reddy, M. S., Verma, R. Development of fluconazole suppositories for the treatment of candida infection of genitourinary tract. Indian J. Pharm. Edu. Res. 2018, 52, S16–S22; https://doi.org/10.5530/ijper.52.4s.71.Search in Google Scholar

3. Healy, B., Barnes, R. Topical and oral treatments for fungal skin infections. In Drug Review Fungal Skin Infections. Prescriber 5 April 2006; pp. 30–43. URL: www.escriber.com. https://onlinelibrary.wiley.com/doi/pdf/10.1002/psb.360 (Accessed on Nov 18, 2021).10.1002/psb.360Search in Google Scholar

4. Vlachadis, N., Iliodromiti, Z., Vrachnis, N. Oral fluconazole during pregnancy and risk of birth defects. N. Engl. J. Med. 2013, 369, 2061; https://doi.org/10.1056/NEJMc1312226.Search in Google Scholar

5. Mølgaard-Nielsen, D., Pasternak, B., Hviid, A. Use of oral fluconazole during pregnancy and the risk of birth defects. N. Engl. J. Med. 2013, 369, 830–839; https://doi.org/10.1056/NEJMoa1301066.Search in Google Scholar

6. Sørensen, H. T., Nielsen, G. L., Olesen, C., Larsen, H., Steffensen, F. H., Schønheyder, H. C., Olsen, J., Czeizel, A. E. Risk of malformations and other outcomes in children exposed to fluconazole in utero. Br. J. Clin. Pharmacol. 1999, 48, 234–238; https://doi.org/10.1046/j.1365-2125.1999.00989.x.Search in Google Scholar

7. Helal, D. A., Abd El-Rhman, D., Abdel-Halim, S. A., El-Nabarawi, M. A. Formulation and evaluation of fluconazole topical gel. Int. J. Pharm. Pharmaceut. Sci. 2012, 4, 176–183.Search in Google Scholar

8. Sawant, B., Khan, T. Recent advances in delivery of antifungal agents for therapeutic management of candidiasis. Biomed. Pharmacother. 2017, 96, 1478–1490; https://doi.org/10.1016/j.biopha.2017.11.127.Search in Google Scholar

9. Fernandes, A. V., Pydi, C. R., Verma, R., Jose, J., Kumar, L. Design, preparation and in vitro characterization of fluconazole loaded nanostructured lipid carriers. Braz. J. Pharm. Sci. 2020, 56, 14, e18069; https://doi.org/10.1590/s2175-97902019000318069.Search in Google Scholar

10. Food and Drug Administration Use of long-term, high-dose diflucan (fluconazole) during pregnancy may be associated with birth defects in infants. URL: http://www.fda.gov/Drugs/DrugSafety/ucm266030.htm (Accessed on Feb 21, 2018).Search in Google Scholar

11. Young, G. L., Jewell, D. Topical treatment for vaginal candidiasis (Thrush) in pregnancy. Cochrane Database Syst. Rev. 2001, 4, CD000225; https://doi.org/10.1002/14651858.CD000225.Search in Google Scholar

12. Kumar, L., Reddy, M. S., Shirodkar, R. K., Pai, G. K., Krishna, V. T., Verma, R. Preparation and characterisation of fluconazole vaginal films for the treatment of vaginal candidiasis. Indian J. Pharmaceut. Sci. 2013, 75, 585–590.Search in Google Scholar

13. O-Prasertsawat, P., Bourlert, A. Comparative study of fluconazole and clotrimazole for the treatment of vulvovaginal candidiasis. Sex. Transm. Dis. 1995, 22, 228–230; https://doi.org/10.1097/00007435-199507000-00005.Search in Google Scholar

14. Souto, E. B., Wissing, S. A., Barbosa, C. M., Müller, R. H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 2004, 278, 71–77; https://doi.org/10.1016/j.ijpharm.2004.02.032.Search in Google Scholar

15. Gupta, M., Vyas, S. P. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem. Phys. Lipids 2012, 165, 454–461; https://doi.org/10.1016/j.chemphyslip.2012.01.006.Search in Google Scholar

16. Sanad, R. A., Abdelmalak, N. S., Elbayoomy, T. S., Badawi, A. A. Formulation of a novel oxyybenzone-loaded nanostructured lipid carriers (NLCs). AAPS PharmSciTech 2010, 11, 1684–1694; https://doi.org/10.1208/s12249-010-9553-2.Search in Google Scholar

17. Patel, J., Patel, B., Banwait, H., Parmar, K., Patel, M. Formulation and evaluation of topical aceclofenac gel using different gelling agent. Int. J. Drug Dev. 2011, 3, 156–164.Search in Google Scholar

18. Chakole, C. M., Shende, M. A., Khadatkar, S. N. Formulation and evaluation of novel combined halobetasol propionate and fusidic acid ointment. Int. J. Chem. Tech. Res. 2009, 1, 103–116.Search in Google Scholar

19. Fang, J. Y., Fang, C. L., Liu, C. H., Su, Y. H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 2008, 70, 633–640; https://doi.org/10.1016/j.ejpb.2008.05.008.Search in Google Scholar

20. Cirri, M., Bragagni, M., Mennini, N., Mura, P. Development of a new delivery system consisting in “drug - in cyclodextrin - in nanostructured lipid carriers” for ketoprofen topical delivery. Eur. J. Pharm. Biopharm. 2012, 80, 46–53; https://doi.org/10.1016/j.ejpb.2011.07.015.Search in Google Scholar

21. Chatterjee, A., Kumar, L., Bhowmik, B. B., Gupta, A. Microparticulated anti-HIV vaginal gel: in vitro-in vivo drug release and vaginal irritation study. Pharmaceut. Dev. Technol. 2011, 16, 466–473; https://doi.org/10.3109/10837450.2010.485318.Search in Google Scholar

22. Dash, S., Murthy, P. N., Nath, L. K., Chowdhary, P. Kinetic modelling on drug release from controlled drug delivery systems. Acta Pol. Pharm. 2010, 67, 217–223.Search in Google Scholar

23. Kapileshwari, G. R., Barve, A. R., Kumar, L., Bhide, P. J., Joshi, M., Shirodkar, R. K. Novel drug delivery system of luliconazole – formulation and characterization. J. Drug Deliv. Sci. Technol. 2020, 55, 101302; https://doi.org/10.1016/j.jddst.2019.101302.Search in Google Scholar

24. Murkute, A. V., Sahu, M. S., Mali, P. Y., Rangari, V. D. Development and evaluation of formulations of microbial biotransformed extract of tobacco leaves for hair growth potential. Phcog. Res. 2010, 2, 300–303; https://doi.org/10.4103/0974-8490.72328.Search in Google Scholar

25. Premkumar, A., Muthukumaran, T., Ganesan, V. Formulation and evaluation of cream containing antifungal agents, antibacterial agents and corticosteroids. J. Drugs Med. 2014, 66, 5–16; https://doi.org/10.15254/H.J.D.Med.6.2014.131.Search in Google Scholar

26. Basha, B. N., Prakasam, K., Goli, D. Formulation and evaluation of gel containing fluconazole-antifungal agent. Int. J. Drug Dev. Res. 2011, 3, 109–128.Search in Google Scholar

27. Blokhina, S., Ol’khovich, M., Sharapova, A., Perlovich, G. Experimental investigation of fluconazole: equilibrium solubility and sublimation. J. Chem. Thermodyn. 2020, 151, 106243; https://doi.org/10.1016/j.jct.2020.106243.Search in Google Scholar

28. Kunjwani, H., Sabale, P., Sabale, V. Formulation and in vitro evaluation of the topical antiageing preparation of the fruit of Benincasa hispida. J. Ayurveda Integr. Med. 2011, 2, 124–128; https://doi.org/10.4103/0975-9476.85550.Search in Google Scholar

29. Garg, A., Aggarwal, D., Garg, S., Singla, A. K. Spreading of semisolid formulations-An update. Pharmaceut. Technol. 2002, 26, 84–105.Search in Google Scholar

30. Garg, T., Rath, G., Goyal, A. K. Comprehensive review on additives of topical dosage forms for drug delivery. Drug Deliv. 2015, 22, 969–987; https://doi.org/10.3109/10717544.2013.879355.Search in Google Scholar

31. The research on oleic acid for hair loss. URL: https://ugro.com/the-research-on-oleic-acid-for-hair-loss/ (Accessed on 10 September 2021).Search in Google Scholar

Received: 2022-01-09
Accepted: 2022-02-11
Published Online: 2022-04-05
Published in Print: 2022-05-25

© 2022 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 2.2.2026 from https://www.degruyterbrill.com/document/doi/10.1515/tsd-2022-2422/html?lang=en
Scroll to top button